Id |
Subject |
Object |
Predicate |
Lexical cue |
T20 |
0-12 |
Sentence |
denotes |
Introduction |
T21 |
13-171 |
Sentence |
denotes |
During the fag end of 2019, Wuhan – the most densely populated city and capital of Hubei Province – China was witnessing pneumonia whose etiology was unknown. |
T22 |
172-302 |
Sentence |
denotes |
At the beginning of 2020, the pathogen was successfully identified and was named as the 2019 novel corona virus (2019-nCoV) [1,2]. |
T23 |
303-559 |
Sentence |
denotes |
Later, on 20 February 2020, the International Committee on Taxonomy of Viruses (ICTV) named it as Severe Acute Respiratory Syndrome Corona virus 2 (SARS-CoV-2), a new variant of SARS-CoV, and the disease caused was corona virus disease 2019 (COVID-19) [3]. |
T24 |
560-635 |
Sentence |
denotes |
Since then the whole world is on ‘High Alert’ due to this new viral threat. |
T25 |
636-725 |
Sentence |
denotes |
Millions of people have been (self) quarantined to prevent it from further spreading [4]. |
T26 |
726-808 |
Sentence |
denotes |
Nonetheless, the individuals infected by corona virus are augmenting everyday [5]. |
T27 |
809-897 |
Sentence |
denotes |
There are absolutely no drugs that are approved by regulatory agencies across the globe. |
T28 |
898-1037 |
Sentence |
denotes |
In India, the Indian Council of Medical Research (ICMR) strongly recommended the usage of hydroxychloroquine for asymptomatic purposes [6]. |
T29 |
1038-1264 |
Sentence |
denotes |
Followed by this development, emergency use authorization was granted by United States Food and Drug Administration (USFDA) to promote the usage of chloroquine phosphate or hydroxychloroquine sulfate for treating COVID-19 [7]. |
T30 |
1265-1430 |
Sentence |
denotes |
World Health Organization (WHO) identified and recommended usage of remdesivir, lopinavir–ritonavir with or without interferon, immunotherapy, and recuperative sera. |
T31 |
1431-1558 |
Sentence |
denotes |
WHO also launched SOLIDARITY trials for the above-prescribed drugs to support that they are effective in treating COVID-19 [8]. |
T32 |
1559-1777 |
Sentence |
denotes |
In addition, novel chemical entities against the corona virus protease were also proposed by some researchers [9] and some have proposed various integrated Chinese and Western medicines for treating this pandemic [10]. |
T33 |
1778-1850 |
Sentence |
denotes |
While the research is going on to identify an active agent for COVID-19. |
T34 |
1851-1957 |
Sentence |
denotes |
Identifying the mode of delivering the active moieties to patients and healthy subjects cannot be ignored. |
T35 |
1958-2113 |
Sentence |
denotes |
At present, there are several drug delivery systems, whereas the most novel and transformative drug delivery/carrier system is orodispersible films (ODFs). |
T36 |
2114-2141 |
Sentence |
denotes |
European Pharmacopoeia (Ph. |
T37 |
2142-2278 |
Sentence |
denotes |
Eur.) defines ODFs as ‘single or multilayered sheets of suitable materials, to be placed in the mouth where they disperse rapidly’ [11]. |
T38 |
2279-2453 |
Sentence |
denotes |
They are a type of oromucosal preparations which are ultra-thin, elegant, stamp sized, portable, patient friendly, and attractive dosage forms across all the age groups [12]. |
T39 |
2454-2626 |
Sentence |
denotes |
Clinical Data Interchange Standards Consortium (CDISC) defines ODFs as ‘A thin layer or coating which is susceptible to being dissolved when in contact with a liquid’ [13]. |
T40 |
2627-2805 |
Sentence |
denotes |
On the contrary, United States Pharmacopoeia (USP) employs a different terminology and called them as ‘Oral Films’ and defined as ‘Thin sheets that are placed in the oral cavity. |
T41 |
2806-2838 |
Sentence |
denotes |
They contain one or more layers. |
T42 |
2839-2884 |
Sentence |
denotes |
A layer might or might not contain API’ [14]. |
T43 |
2885-3076 |
Sentence |
denotes |
ODFs undergo rapid disintegration/dissolution and are usually swallowed along with saliva and a small amount of the drug gets absorbed via the oral mucosa due to its high vasculature [15,16]. |
T44 |
3077-3270 |
Sentence |
denotes |
ODFs are excellent and attractive carriers for delivery of various over the counter (OTC) or prescription drugs [17], herbal extracts [18–21], vaccines [22], probiotics [23], and vitamins [24]. |
T45 |
3271-3673 |
Sentence |
denotes |
Drugs are either directly introduced [25–28] in the formulation of ODFs or size reduced and converted to solid dispersions [29] or nanoparticles [30,31] or solid lipid microparticles [32] or micronized and surface modified using silica [33] which not only help in enhancing the amount of drug that could be loaded on to ODFs but also help in enhancing the release rate and, bioavailability of the drug. |
T46 |
3674-3784 |
Sentence |
denotes |
At present, ODFs are used as an excellent carrier system for delivering various therapeutically active agents. |
T47 |
3785-3896 |
Sentence |
denotes |
The composition of ODFs includes a drug substance (natural or synthetic), a film-forming agent and plasticizer. |
T48 |
3897-3996 |
Sentence |
denotes |
Additionally, it also includes saliva stimulating agent, organoleptic agents, and stabilizers [12]. |
T49 |
3997-4160 |
Sentence |
denotes |
The critical quality characteristics of ODFs are its appearance, stability, water content, uniformity of the active agent, color, taste, aftertaste, and mouthfeel. |
T50 |
4161-4242 |
Sentence |
denotes |
Most importantly, it shall not cause irritation of mucosa when administered [34]. |
T51 |
4243-4488 |
Sentence |
denotes |
The authors provided an overview on characterization of ODFs to determine various quality parameters of ODFs and also introduced a 3D printed disintegration test apparatus for testing the disintegration time of ODFs using sensor technology [35]. |
T52 |
4489-4703 |
Sentence |
denotes |
ODFs are capable for drug delivery in patients with swallowing problems, mentally retarded patients, subjects with Parkinson’s disease, bed-ridden patients, oral cancer patients, and uncooperative patients [36–38]. |
T53 |
4704-4902 |
Sentence |
denotes |
The present review is focused on critically analyzing the potential of ODFs as carriers for delivering antiviral drugs/herbs/vaccines with a potential for treatment of COVID-19, the global pandemic. |